FirstWord

If it successfully closes the offering, Lycia will be the fifth biotech to IPO this quarter.

The collaboration will explore use cases that could improve clinical-trial efficiency, including identifying eligible patients earlier and easier, across several disease areas.

RAP-219, a TARPγ8-specific AMPA receptor negative allosteric modulator, achieved the primary endpoint of a mid-stage study for the treatment of bipolar mania.

Emvistegrast, an α4β7 integrin inhibitor, met its primary endpoint in the Phase II SWIFT study in ulcerative colitis (UC).

The partners will use generative and predictive AI to refine the lipid components of drug-carrying nanoparticles, although specific disease targets have yet to be disclosed.

Presentation will feature new preclinical data of CPTx’s proprietary immune-quiet DNA vector delivered non-virally with targeting lipid nanoparticlesMunich, Germany & San Francisco, California - Octob...

In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, ...

Palisade Bio Presents Rapid Endoscopic Improvement and New ...

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ES...

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...